Evotec, UCB in CNS deal

Evotec AG (Xetra:EVT) will use its drug discovery technologies to identify small molecule modulators of CNS targets selected by UCB Group (Euronext:UCB). Under the three-year deal, Evotec will receive research funding and will be eligible for milestones and royalties. Details were not disclosed. Evotec rose EUR 0.12 to EUR 2.72 on Thursday, while UCB was up EUR 0.37 to EUR 32.15. ...